< back to press releases

Critical Diagnostics Announces key promotions

San Diego, CA, USA – January, 8, 2016 – Critical Diagnostics,makers of the Presage® ST2 Assay and ASPECT-PLUS™ rapid ST2 test, today announced two promotions within the company’s management team. Dennis Dalangin, formerly Vice President, Global Marketing has been promoted to Vice President, Operations and Global Marketing, and Greg Cerra, formerly Director, Regulatory Affairs has been promoted to Vice President, Regulatory Affairs and Quality Systems.

“Through their professionalism and dedicated efforts, both Dennis and Greg have each made significant contributions to the company’s growth,” comments James Snider, President, Critical Diagnostics. “Both executives have become an integral part of the company’s management team and I’m confident will be able to help us continue to achieve our goals.”

Mr. Dalangin joined Critical Diagnostics in 2012 as the Vice President of Global Marketing, and, in his newly expanded role as Vice President, Operations and Global Marketing will now also be responsible for the day to day management of the operations at the San Diego headquarters, which include three contract manufacturers, and a logistics fulfillment partner in Europe and US.  

Mr. Cerra joined Critical Diagnostics in 2015 as the Director, Regulatory Affairs, and was instrumental in the company’s efforts to CE Mark its next generation platform, ASPECT-PLUS, a new rapid ST2 test.   With his promotion to Vice President, Regulatory Affairs and Quality Systems, Mr. Cerra will be responsible for the global strategy and efforts surrounding the registration and clearance of the company’s products in key markets.


Heart failure is a condition in which the heart can't pump enough blood to meet the body's needs. As noted by Professor Eugene Braunwald, a keynote speaker at the 2015 HFA Congress, in his paper “The War Against Heart Failure,” in The Lancet, Heart failure is a global problem with an estimated prevalence of 38 million patients worldwide, and a number that is increasing with the aging of the population.


ST2 is a soluble protein expressed by the heart in response to disease or injury. It is reflective of ventricular remodeling and cardiac fibrosis associated with heart failure. ST2 is not adversely affected by confounding factors such as age, body mass index and impaired renal function. ST2 levels change quickly in response to changes in the patient’s condition—thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust care. The Presage ST2 Assay is CE marked and FDA cleared. The ASPECT-PLUS rapid ST2 test is CE marked.


Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. Critical Diagnostics has distribution partners in some 50 countries, covering two-thirds of the world’s population.

Dennis Dalangin, VP, Operations and Global Marketing

Telephone: +1 (877) 700-1250
Email: ddalangin@criticaldiagnostics.com